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Abstract: Transition metals have essential roles in brain structure and function, and are associated
with pathological processes in neurodegenerative disorders classed as proteinopathies. Synchrotron
X-ray techniques, coupled with ultrahigh-resolution mass spectrometry, have been applied to study
iron and copper interactions with amyloid β (1–42) or α-synuclein. Ex vivo tissue and in vitro
systems were investigated, showing the capability to identify metal oxidation states, probe local
chemical environments, and localize metal-peptide binding sites. Synchrotron experiments showed
that the chemical reduction of ferric (Fe3+) iron and cupric (Cu2+) copper can occur in vitro after
incubating each metal in the presence of Aβ for one week, and to a lesser extent for ferric iron
incubated with α-syn. Nanoscale chemical speciation mapping of Aβ-Fe complexes revealed a spatial
heterogeneity in chemical reduction of iron within individual aggregates. Mass spectrometry allowed
the determination of the highest-affinity binding region in all four metal-biomolecule complexes.
Iron and copper were coordinated by the same N-terminal region of Aβ, likely through histidine
residues. Fe3+ bound to a C-terminal region of α-syn, rich in aspartic and glutamic acid residues, and
Cu2+ to the N-terminal region of α-syn. Elucidating the biochemistry of these metal-biomolecule
complexes and identifying drivers of chemical reduction processes for which there is evidence ex-vivo,
are critical to the advanced understanding of disease aetiology.
Keywords: Alzheimer’s disease; Parkinson’s disease; amyloid β; α-synuclein; copper; iron; mass
spectrometry; electrospray ionization; X-ray; spectromicroscopy
1. Introduction
There is a long-established association between aberrant protein deposition in neurodegenerative
disorders, and disrupted metabolism of metals. The extent to which metal-protein interactions are a
contributing factor in disease pathogenesis remains an active research question, arguably due to the
complexity of the systems concerned and the level of analytical challenge associated with their study.
The proteinopathies include many forms of dementia and movement disorders, and
disease-specific patterns of aberrant protein deposition are integral diagnostic hallmarks in disorders
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such as Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, multiple system
atrophy, and others. A causative role has been postulated for the well-documented protein cleavage
and misfolding that arises in disorders, such as Alzheimer’s and Parkinson’s disease (for example,
the amyloid cascade hypothesis [1]), where increased central nervous system (CNS) concentrations
and subsequent aggregation of amyloid β, a 4.5 kDa peptide, and α-synuclein, a 14 kDa protein,
are observed. The hallmarks of these diseases include amyloid β forming extracellular deposits as
senile plaques, and α-synuclein intracellular aggregates (Lewy bodies), respectively. The patterns
and forms of amyloid and synuclein deposition are a factor in post-mortem classification of these
neurodegenerative disorders. Attempts to intervene in the disease progression by targeting amyloid
burden in isolation (typically using selective monoclonal antibodies) have consistently failed [2–5].
Metals play many essential roles in the human brain [6,7]. There is long-standing, but incomplete,
evidence of disrupted metal ion metabolism and localized accumulation in neurodegenerative disorders
(including the abundant biometals such as calcium, the essential transition metals, and non-essential
metals that can enter the CNS such as aluminium). These observations have motivated the development
of chelating drugs. Clinical trials of approaches successful in treating systemic overload disorders
(e.g., iron chelation in haemochromatosis, copper chelation in Wilson’s disease), have been extended to
disorders primarily of the CNS. Chelation trials to date have shown mixed results for the application
to neurodegenerative disorders, but some have delivered promising results in modulating iron and
copper [8–10].
In this context, it is of fundamental importance to consider the interplay between metals
and peptides. It is well-established that amyloid β and α-synuclein deposits in human brain
tissue are associated with metal accumulations, and these metals can affect the aggregation kinetics
of amyloidogenic peptides and proteins through the induction of conformational change and/or
metal-catalysed oxidation of the protein backbone [11–23]. It has been postulated that binding
of metallic counter-ions neutralises charge repulsion, permitting the formation of more compact
and structured conformations, such as those that comprise filamentous Lewy bodies [23]. In vitro
studies have demonstrated accelerated α-synuclein fibrillation associated with both iron [11,24] and
copper [11,23,25] co-incubation.
Furthermore, it has been shown in ex vivo tissue studies that the metal-containing phases within
senile plaques and Lewy bodies are often chemically reduced and therefore reactive, suggesting that
the metal-catalysed production of radicals and reactive oxygen species might contribute to neuron
death [13,14,20,26–30]. There is, therefore, a pressing need to understand the interactions of transition
metal ions with amyloid β and α-synuclein on a molecular scale, including the way these interactions
affect the oxidation states of the metals, supported by the evidence of chemical reduction in-vitro or
within cultured cells [26,31,32].
Studying the spatial distribution of trace metals in solid samples (such as brain tissues and
their derivatives) poses significant challenges, and only a handful of methods can simultaneously
provide information on the metals’ chemical state. Synchrotron X-ray methods have received
considerable attention in this context [7,33]. X-ray techniques using hard, and more recently soft, X-rays
have been successfully utilized to examine neurodegenerative disease tissues ex vivo [7,13,34–36].
Utilizing unique structures and natural contrast in samples is important to maximise the success of
these studies where non-destructive methods are employed, as the same region of a sample may be
analysed multiple times. In the example of brain tissue analysed for this article (Figure 1), neurons
from the substantia nigra, naturally pigmented with granules of neuromelanin (NM), were used,
as the metabolism of metals in this region is of interest, particularly in the context of Parkinson’s
disease [37–39] and NM—a biological polymer formed by autoxidation of dopamine—provides
useful contrast.
Micro-focus X-ray fluorescence (µXRF) mapping provides a means to establish simultaneously
the distribution of multiple trace metal elements at spatial resolutions of a few microns. Synchrotron
X-rays can also be tuned in energy with great precision to excite electrons from core atomic shells,
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causing an abrupt increase in photo-absorption at energies equal to the shell binding energy [7,40].
This increase is recognized as an ionization edge in the X-ray absorption spectrum, and an analysis
of the characteristic shape of the absorption spectrum near the ionization edge is known as X-ray
absorption near-edge spectroscopy (XANES). XANES focuses on the absorption fine structure near the
edge corresponding to the excitation energy of an inner-shell electron to an unoccupied orbital. When
probing metal K-shell electrons, this typically requires the use of a high-energy (> 5 keV/photon) hard
X-ray beam, while metal L-shell electrons can be probed using a lower energy soft X-ray beam (< 5
keV). These X-ray techniques have the benefit of providing information on the metal oxidation state,
and are sensitive to the types and numbers of coordinated ligand atoms and metal-ligand distances.
With sufficiently pure samples, it may be possible to determine the structures from first principles
using extended X-ray absorption fine structure (EXAFS). XANES analysis with a micro-focused beam
may be performed in situ without the requirement for histological staining or contrast agents (which
are likely to alter the native biochemistry), and for the equivalent spatial resolution, the typical beam
damage is lower from synchrotron X-ray methods than from conventional electron beam methods [7].
XANES spectra can be collected in the transmission or fluorescence mode, though the fluorescence
mode is typically preferred for low (approximately ppm) concentrations [40], and XANES acquisition
can be informed by prior XRF mapping, or even integrated into a XANES mapping experiment at
many micro-focus beamlines.
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was also confirmed. This level f attenuation was demonstrated, by the use of repeated scanning, to 
mitigate photo-reducti n for all four experiment co ditions, and 0.5 mm Al attenuation was used in 
all subsequent measurements of copper XANES. The equivalent level of attenuation required at the 
iron edge was 0.1 mm Al.  
 
Figure 1. (a) Optical image showing melanised dopaminergic neurons in PD substantia nigra tissue. 
X-ray fluorescence maps of the area shown in (a) were collected using a 5 μm beam and a 0.1 mm Al 
foil attenuator. XRF maps are shown for (b) iron, (c) copper, and (d) zinc at their respective K-edges. 
(e) Iron XANES from the individual neuron highlighted in (a), showing successive scans on the same 
area to monitor possible photo-reduction, with the results from linear combination fitting of XANES 
spectra alongside experimental standards (a range of Fe0/Fe2+/Fe3+ standards and ferritin-bound Fe3+ 
iron). The repeated traces were identical within measurement uncertainty (<2%), and the absorption 
edge region (−20 eV below to +80 eV above the edge) fitted well with 100% FeCl3, with χ2 values of 
0.11 and 0.07 obtained for the initial and repeat scans, respectively. Traces were subjected to an edge-
step normalization and flattened using Athena fitting software. Traces are vertically offset for clarity. 
3.1.1. XANES of Iron in Human Brain Tissue 
In order to perform XANES of iron from the sites of interest in human brain tissue, μXRF analysis 
was first used to make multi-metal maps over the regions of human brain tissue. XANES analysis 
was then performed to investigate the chemical state of the metals. In the example shown in Figure 
1, substantia nigra tissue (donated post-mortem from a confirmed case of Parkinson’s disease) 
retained some neuromelanin-pigmented cell bodies (and in some cases neuromelanin released into 
the extra-cellular matrix), showing elevation of iron, copper, and zinc levels relative to the 
surrounding tissue. This example is provided to showcase μXRF analysis of metal distribution in 
tissues, aided by the endogenous contrast from the pigmented neuromelanin which provides 
information about the tissue structure. These regions of concentrated metals map to the distribution 
of pigmentation and are consistent with the high affinity of neuromelanin for transition metals which 
may impact neuronal vulnerability [37–39]. 
The beam exposure at each pixel during XRF mapping was short (<1 s), but there is scope when 
performing subsequent XANES at the sites of interest (e.g., at the inset region outlined in Figure 1(a)) 
for photo-reduction of the metals to occur. The repeat scans using 0.1 mm Al attenuation were 
performed at the site of interest shown in Figure 1(a), demonstrating that XANES at the iron K-edge 
was unchanged within experimental error (<2%). The fitting of the repeat-scanned region in the NM-
rich neuron (blue and orange traces in Figure 1(e)) with FeCl3 (shown as a solid black line) supports 
the interpretation that NM-bound iron is predominantly in ferric form in these pigmented regions. 
This finding is supported by prior reports [34]. 
Figure 1. (a) Optical image showing melanised dopaminergic neurons in PD substantia nigra tissue.
X-ray fluorescence maps of the area shown in (a) were collected using a 5 µm beam and a 0.1 mm Al
foil attenuator. XRF maps are shown for (b) iron, (c) copper, and (d) zinc at their respective K-edges. (e)
Iron XANES from the individual neuron highlighted in (a), showing successive scans on the same area
to monitor possible photo-reduction, with the results from linear combination fitting of XANES spectra
alongside experimental standards (a range of Fe0/Fe2+/Fe3+ standards and ferritin-bound Fe3+ iron).
The repeated traces were identical within measurement uncertainty (<2%), and the absorption edge
region (−20 eV below to +80 eV above the edge) fitted well with 100% FeCl3, with χ2 values of 0.11
and 0.07 obtained for the initial and repeat scans, resp ctively. Traces were subjected to an edge-step
normalization nd fl ttened using Athena fitting software. Traces are vertically offset for clarity.
A further synchrotron X-r y approach emerging as a powerful tool for the analysis of heterogeneous
biological samples is soft X-ray spectromicroscopy, in the form of scanning transmission X-ray
microscopy (STXM). This approach combines spectroscopic analysis with high-resolution microscopy
enabling the chemical speciation of a sample material to be determined to a spatial resolution of
approximately 20 nm. The operational energy range of STXM microscopes spans both organic (e.g., C,
together with N, O and P) and inorganic (metal) absorption edges, allowing for the correlations between
metal chemistry and specific biological structures to be identified. Furthermore, magnetically sensitive
Cells 2019, 8, 1231 4 of 26
STXM X-ray magnetic circular dichroism (XMCD) allows for site-specific magnetic characterization of
metal phases within imaged regions of interest [13].
These X-ray methods are often considered non-destructive as, unlike imaging mass spectrometry
methods, they do not rely on ablation of the sample. Sample preservation facilitates correlative imaging
(for example, light and electron microscopy) to be performed following X-ray analysis. In addition,
these approaches require no aldehyde fixatives, contrast agents or dyes, thereby preserving native
sample chemistry to a greater extent than traditional approaches used to image biological tissues [41].
However, despite their non-destructive nature, it is necessary to carefully control the X-ray dose used
in this type of experiment to ensure a reliable and reproducible chemical analysis.
Mass spectrometry (MS) is an important technique used to study metalloproteins on a molecular
(atomic) scale, particularly in combination with electrospray ionisation (ESI) [42–46]. Under optimised
conditions, ESI can transfer intact metal-protein complexes into the gas phase, where their molecular
mass can be measured very accurately. This also allows the determination of the oxidation state of
the metal. For a metal-free protein M, the electrospray process produces a multiply charged cation
[M + nH]n+. In other words, the charges are provided by the addition of protons, each possessing
a mass of approximately 1.0073 Da. If a multiply-charged metal ion is attached to the protein, the
ion produced instead is [M + Metal + nH]m+, and the oxidation state of the metal equals (m−n), i.e.,
the charges not accounted for by the proton addition are carried by the metal, the mass of which
is essentially independent of the oxidation state. While this approach is very straightforward, two
caveats should be noted. First of all, the ESI source is essentially an electrochemical cell, and redox
reactions within this cell cannot be ruled out a priori. Second, as ionisation typically occurs under
atmospheric conditions, there is a window of a few milliseconds during which the oxidation of very
sensitive species can occur. Furthermore, ESI-MS requires highly purified samples in solution, and
is incompatible with most of the non-volatile buffers and salts commonly used in molecular biology.
Despite these limitations, ESI-MS offers several unique benefits, as different co-occurring protein
isoforms and metal-bound states can be resolved, and these can be isolated for further analysis in
tandem MS experiments. In this approach, an ion is isolated and subjected to gas-phase activation, for
which several methods exist [47–49]. This induces the fragmentation of the amide backbone of the
peptide or protein, and the masses of the resulting fragments are measured. By carefully controlling
the fragmentation, it is possible in some cases to cleave the backbone while preserving protein-metal
interactions, and as a result, the fragments that contain the residue(s) that interact(s) with the metal,
show a characteristic mass increase [50–53]. As such, careful analysis of the fragmentation pattern can
provide clues about the sequence region in which binding occurs.
This work demonstrates a suite of complementary approaches (Table 1) including X-ray
spectromicroscopy, mass spectrometry, and supporting electron microscopy, to investigate the properties
of metals interacting with peptides integral to the hallmarks of neurodegenerative disorders.
In the example applications, unstained (label-free) post-mortem brain tissue was pre-imaged
using µXRF to determine the oxidation state of iron in the regions of interest. Subsequently, hard X-ray
XANES and soft X-ray spectromicroscopy, ESI-MS, and electron microscopy were used to analyse
complexes of iron and copper with Aβ(1–42) and α-syn formed in vitro. In particular, the chemical
environment of the metals in these complexes (i.e., the primary amino acid residue binding sites)
was studied as well as the effect of binding and co-incubation on the oxidation state of the metals.
A potential concern when using energetic X-ray probes to measure oxidation state chemistry is the
possibility of X-ray photo-reduction. There are a few systematic reports into X-ray beam induced
changes to sample chemistry in these systems of interest, but this concern is critical if robust insights
are to be obtained. This study showed through a careful analysis and control of the X-ray exposure
conditions, how such effects can be identified and successfully mitigated against.
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Table 1. Summary of primary techniques.
Technique Abbreviation Description
Mass Spectrometry MS
Electrospray ionization (ESI) tandem MS is used to
determine regions on peptides where metals bind, by
analyzing the molecular masses of fragments where the
amide backbone of the peptide has been cleaved while
preserving protein-metal interactions. The fragmentation
pattern indicates the binding region(s), as the fragments
containing the residue(s) that interact(s) with the metal
show a characteristic mass increase.
Scanning Transmission X-ray
Microscopy STXM
Synchrotron soft X-ray microscopy is used in
transmission mode to obtain images at tens of nanometer
spatial resolution, acquired sequentially in stacks as a
function of energy. These data contain spectral
information about the chemistry of each region of
interest selected within the image.
X-ray Absorption Near-Edge
Spectroscopy XANES
Synchrotron hard X-ray microscopy is used in
fluorescence mode to obtain energy scans from elements
of interest, where the structure of the spectrum is
sensitive to the local chemical environment of the
scattering element.
Transmission Electron Microscopy TEM
Electron beam imaging is used to investigate the forms of
peptide aggregate present in the samples analyzed by
MS, STXM, and XANES.
2. Materials and Methods
2.1. Materials for In-Vitro Experiments
Synthetic Aβ(1–42) was acquired from Bachem (Bubendorf, Switzerland), the same source the
authors have used in previous research [28,29]. The peptide was produced by solid-phase peptide
synthesis using the Fmoc strategy followed by trifluoroacetic acid-mediated cleavage. Recombinant
140-residue α-synuclein (catalogue #AG938), CuCl, CuSO4, FeCl2, FeCl3, Fe(III) ammonium citrate,
glutathione, 1,10-phenanthroline, nitrilotriacetic acid, and hydroxylamine hydrochloride were
purchased from Sigma (Dorset, UK). As described in Section 3.3, one of the key techniques used in this
work was ultrahigh-resolution tandem mass spectrometry, enabling the measurement of the masses of
the intact Aβ(1–42) and α-syn as well as fragments produced in the gas phase with accuracy better
than 1 part-per-million (see Tables A1–A4 in Appendix D). Hence, these data establish the high purity
as well as the mass and sequence of the α-syn used in this work.
Peptide and metal stocks were diluted in a modified Krebs-Henseleit (KH) buffer (pH 7.4; 100 mM
PIPES, 118.5 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.4 mM CaCl2, 11 mM glucose and all Sigma
Aldrich) modelled on the abundance of these elements reported in the cerebrospinal fluid of the central
nervous system [17]. PIPES was utilized as a buffering agent as it does not interact strongly with
metal ions.
2.1.1. For XANES Experiments
As the Fe(II) ion in aqueous solution is sensitive to oxidation by atmospheric oxygen, a stable
Fe(II) reference standard for XANES was produced by making a solution containing a 1:3 molar ratio
of FeCl2:1,10-phenanthroline, as, in the resulting complex, this ligand protects the iron center from
oxidation. The Fe(II) oxidation state of iron in this complex was confirmed using MS (Appendix A
Figure A1). Similarly, to stabilize the Cu(I) ion in aqueous solution, the appropriate amount of
anhydrous CuCl to yield a concentration of 0.77 mM was dissolved in a 3.25 mM solution of glutathione
(i.e., resulting in a 1:4 mol ratio), following a published procedure [54].
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2.1.2. For MS Experiments
The reducing agent hydroxylamine hydrochloride was added in a 1:2 ratio with the metal to
stabilize Fe(II) on the required timescale. To stabilize Fe(III) in solution at pH 7.4, a 1:1 complex
with nitrilotriacetate (NTA) was used [55]. This complex was produced by dissolving FeCl3 and
H3NTA—both at a concentration of 10 mM—in water, and subsequently adjusting the pH to 7.4 by the
dropwise addition of 1 M aqueous ammonia.
2.1.3. For STXM Experiments
Frozen synthetic Aβ(1–42) was thawed and dissolved in 0.1 M NaOH for 30 min at room
temperature to create a 1 mg/mL (220 µM) Aβ stock. NaOH was used to dissolve Aβ aggregates (that
would otherwise be insoluble at pH 7) that may have formed during the sample storage, ensuring
complete peptide dissolution. Amyloid β stock was diluted in modified KH buffer (pH 7.4) and was
allowed to incubate at 37 ◦C for 48 h before the addition of 18 mM iron(III) nitrate solution. Following
the addition of iron(III), the suspensions of Aβ/iron were incubated at 37 ◦C for a further 30 min before
sampling. The final Aβ and iron concentrations were 35 and 370 µM, respectively. The suspensions of
Aβ/iron were incubated within sealed microcentrifuge tubes.
2.2. Human Tissue
Human brain tissue from the substantia nigra of a confirmed case of Parkinson’s disease was
obtained fresh-frozen from the Canadian Brain Tissue Bank and cryosectioned with an acid-washed
sapphire blade (to avoid any metal contamination) to a thickness of 30 µm, mounted on a
spectroscopically-clean synthetic quartz slide, and air-dried in a class II hood prior to hard X-ray XRF
and XANES analysis. The use of this tissue was conducted in accordance with the Declaration of
Helsinki, under approval 07.MRE08.12 from North West Haydock Park Research Ethics Committee.
2.3. Hard X-ray Spectromicroscopy
Hard X-ray synchrotron XANES data, preceded by µXRF data, where required for the localization
of regions of interest, were collected on the microfocus beamline I18 at the Diamond Light Source
(Oxfordshire, UK).
2.3.1. For µXRF
A primary incident synchrotron X-ray beam of 13 keV was used to stimulate fluorescence emission
simultaneously from all accessible elements in each sample analyzed, with the full fluorescence
spectrum acquired for each pixel of every map. A focused X-ray beam diameter of 5 µm2 defined the
maximum spatial resolution used. An optical camera was focused on the sample during mapping to
allow the metal distribution to be correlated with anatomical tissue structure. All fluorescence maps
were generated after using PyMCA software to subtract the background and fit the individual peaks.
2.3.2. For XANES
A series of solutions was prepared for analysis containing 35 µM Aβ or α-syn, and 440 µM FeCl3
or CuSO4 in modified KH buffer, using a protocol previously described for studies of Aβ [28,29].
An aliquot was taken immediately after mixing to provide the t0 data point, and the rest of the sample
was then placed in an incubator at 37 ◦C inside a sealed 1.5 mL microcentrifuge tube for 7 days to
provide the t1wk data point. In preparation for XANES acquisition, 2.5 µL of the sample was deposited
on a thin Ultralene film and allowed to dry (approximately 1 h at 37 ◦C). This procedure was repeated
three times per spot in order to deposit enough of the sample to obtain XANES spectra in fluorescence
mode with reasonable signal-to-noise (S/N) ratios. Except for the photo-reduction tests, the incoming
hard X-ray beam was attenuated using 0.5 mm (when acquiring near the Cu edge) or 0.1 mm (Fe
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edge) of aluminum foil to minimize beam damage. XANES traces were subjected to an edge-step
normalization and flattened using the standard protocol in the Athena fitting software [56].
2.4. Soft X-ray Spectromicroscopy
Soft X-ray spectromicroscopy was used for STXM examination of the nanoscale morphology
and chemical composition of Aβ/iron structures formed in vitro. Five µL of the incubated Aβ/iron
suspension (35 µM Aβ) was deposited onto 100 × 100 µm SiO2 membrane windows (DuneSciences;
75 nm thickness), and the excess liquid was removed with filter paper. The membranes were mounted
onto STXM sample plates for X-ray spectromicroscopy. In an effort to maintain the oxidation state of
iron, all sampling and mounting was performed within a nitrogen-filled glove bag, and the samples
were transported to the X-ray microscope in a nitrogen-filled vessel. Prior to sample loading, the STXM
end-station was purged with nitrogen.
The STXM measurements were performed at the Swiss Light Source (Villigen, Switzerland) on
the PolLux beamline using the STXM end-station. The focused X-ray spot size was approximately
20 nm. The energy-specific images were created by raster scanning the sample at the point of the
focused X-ray beam and recording the intensity of the transmitted X-rays. In order to minimize
photon-dose effects, thus best preserving sample chemistry during the STXM measurements, dwell
(exposure) times were kept to a minimum (≤ 4 ms/point). To assess the chemical composition of
Aβ/iron structures at a nanoscale spatial resolution, speciation maps were created by taking paired
images: one at an energy corresponding to a feature of interest (e.g., the amide peak at the carbon
K-edge [288.3 eV]) [57,58] and one a few eV below this feature. The off-peak image was then subtracted
from the on-peak image generating an artefact-free contrast map, displaying the chemical speciation
of the examined region. To provide further information regarding the chemical state of the sample
material, X-ray absorption spectra were created by collecting multiple images, collectively referred
to as a stack, over a desired energy range (in this case the carbon K-edge [280–320 eV] and the iron
L2,3-edge [700–740 eV]). The transmitted X-ray absorption intensities from the stack images were
converted to optical density using regions that did not contain any sample material, thereby removing
background absorption features arising from the beamline. This approach to X-ray spectromicroscopy
allows an X-ray absorption spectrum to be generated from every pixel of a stack image, enabling the
chemical characterization of highly localized regions of interest. Carbon K-edge spectroscopy was
performed prior to higher energy iron L2,3-edge spectroscopy to minimize X-ray induced damage to
carbon structures.
The STXM data were processed using the aXis 2000 software package (http://unicorn.mcmaster.ca/
aXis2000. html). ImageJ software was used to adjust the brightness and contrast of X-ray microscopy
images. (Pseudo) colored composite images were created by converting grey-scale X-ray microscopy
images to false color, before recombining the images as overlays. The iron L2,3-edge X-ray absorption
spectra obtained in these experiments were fitted to a series of reference iron standards (Fe(III),
Fe3O4, and Fe(II), see Appendix B Figure A5) using a non-linear least squares fitting procedure to
provide a quantitative estimate of the iron phases contributing to the experimental data. The reference
standards were appropriately scaled using the factors determined by normalizing the X-ray absorption
intensity for each reference iron phase to the integrated intensity over the iron L2,3 absorption edges, as
previously described [13].
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2.5. Mass Spectrometry
Mass spectrometry was performed to ascertain whether the direct binding of iron and copper ions
to amyloid β and α-synuclein occurred, and if so, controlled fragmentation of the peptide backbone
was used to obtain residue-specific information on the binding region(s) involved. MS analysis of the
Aβ-metal and α-syn-metal complexes was performed using a 12 Tesla Bruker solariX Fourier transform
ion cyclotron resonance (FTICR) instrument, using procedures which we have recently described for
Aβ [59]. These samples were prepared in 20 mM aqueous ammonium acetate, following standard
procedures for native MS [42,44]. The aliquots were maintained at room temperature and transferred
into the gas phase by ESI after approximately 10 min. Approximately 10 µL of sample was transferred
to a glass capillary that was prepared in-house. For ESI, a potential difference of 1 kV was applied
using a nichrome wire inserted in the distal end of the capillary. The instrument was operated at a
nominal resolving power of 400,000 at m/z 400, and the quadrupole mass filter of the instrument was
used to select a precursor ion type for tandem MS experiments. Fragmentation was induced using
either collision-induced (CID) or electron capture dissociation (ECD) depending on the precursor ion.
The peak assignment tables can be found in Appendix D, and additional spectral data for the MS and
X-ray results in this paper are available from the University of Warwick open access research repository
(WRAP) at http://wrap.warwick.ac.uk/127048.
2.6. Transmission Electron Microscopy
The supporting analysis with TEM provided high-resolution images of the peptide/metal structures
analyzed by MS (Appendix A Figure A2) and X-ray spectromicroscopy (Appendix B Figure A6).
TEM was performed on a parallel series of samples taken at fixed time-points from the same aliquots
as those analyzed by MS. A JEOL 2011 LaB6 was used, operating at 200 kV with a GATAN ultrascan
camera. Where required, uranyl acetate was used for contrast. TEM was also carried out for the
samples that had already been analyzed by STXM. For this, a JEOL 1230 microscope operating at
100 kV was used, and no dyes or contrast agents were introduced. STXM was carried out prior to the
TEM analysis to prevent electron beam induced changes to sample chemistry.
3. Results
3.1. Hard X-Ray Analysis
Iron and copper XANES data were acquired from a series of Aβ(1–42) and α-syn aggregates
prepared in-vitro (Sections 2.1 and 2.3), with the aliquots dried on Ultralene membranes for analysis.
The iron XANES analysis was also performed on biological tissue (human brain, Section 2.2), dried
onto Ultralene, using µXRF to first locate regions of interest before acquiring iron XANES scans from
these sites. (In principle, copper XANES can also be acquired from brain tissue, but in practice the
concentration of copper is typically an order of magnitude lower than iron, requiring an additional
method optimization to acquire high-quality XANES spectra that delivers reliable insights into the
copper chemistry; this is work in progress.) XANES analysis enabled the observation of a chemical
reduction of the transition metals arising from two sources: As a result of photo-reduction where
the beam exposure was not controlled, and also arising from the incubation of the metals with
aggregating peptides.
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In preparation for the XANES measurements, we determined the extent to which it was necessary
to control photo-reduction from X-ray beam exposure was determined. Appendix C Figure A7 shows,
for in-vitro prepared α-synuclein with Cu(II), how scan reproducibility and features are increasingly
preserved as the thickness of aluminum foil used upstream to attenuate the incident beam is increased.
The preservation of spectra within the experimental error was observed with 0.5 mm aluminum
attenuation at room temperature and ambient pressure, and sample homogeneity was also confirmed.
This level of attenuation was demonstrated, by the use of repeated scanning, to mitigate photo-reduction
for all four experiment conditions, and 0.5 mm Al attenuation was used in all subsequent measurements
of copper XANES. The equivalent level of attenuation required at the iron edge was 0.1 mm Al.
3.1.1. XANES of Iron in Human Brain Tissue
In order to perform XANES of iron from the sites of interest in human brain tissue, µXRF
analysis was first used to make multi-metal maps over the regions of human brain tissue. XANES
analysis was then performed to investigate the chemical state of the metals. In the example shown in
Figure 1, substantia nigra tissue (donated post-mortem from a confirmed case of Parkinson’s disease)
retained some neuromelanin-pigmented cell bodies (and in some cases neuromelanin released into the
extra-cellular matrix), showing elevation of iron, copper, and zinc levels relative to the surrounding
tissue. This example is provided to showcase µXRF analysis of metal distribution in tissues, aided by
the endogenous contrast from the pigmented neuromelanin which provides information about the
tissue structure. These regions of concentrated metals map to the distribution of pigmentation and are
consistent with the high affinity of neuromelanin for transition metals which may impact neuronal
vulnerability [37–39].
The beam exposure at each pixel during XRF mapping was short (<1 s), but there is scope when
performing subsequent XANES at the sites of interest (e.g., at the inset region outlined in Figure 1a) for
photo-reduction of the metals to occur. The repeat scans using 0.1 mm Al attenuation were performed
at the site of interest shown in Figure 1a, demonstrating that XANES at the iron K-edge was unchanged
within experimental error (<2%). The fitting of the repeat-scanned region in the NM-rich neuron (blue
and orange traces in Figure 1e) with FeCl3 (shown as a solid black line) supports the interpretation that
NM-bound iron is predominantly in ferric form in these pigmented regions. This finding is supported
by prior reports [34].
This example of how µXRF can be used to locate transition metal ion distributions in tissues is
facilitated by a choice of a sample with natural contrast arising from the NM pigment. For µXRF
analysis in this energy range, supporting techniques are required to correlate information about other
organic constituents, including protein aggregates, with the metal ion distributions, for example, optical
microscopy with the introduction of stains where necessary. The sections used for µXRF cannot be
stained in advance because for µXRF, staining would introduce an unacceptable level of contamination.
3.1.2. XANES of Iron and Copper in In-Vitro Systems
XANES from aliquots of the iron or copper co-incubated with amyloid β or α-synuclein was
performed with the attenuated beam protecting against photo-reduction. XANES analysis of these
in-vitro formed aggregates revealed a marked chemical reduction of iron and copper arising from the
co-incubation with Aβ, and to a lesser extent with α-syn, as shown in Figure 2.
A comparison of the four in-vitro systems (Fe or Cu plus Aβ or α-syn) indicated that the increased
tendency for chemical reduction under incubation conditions observed for Aβ was mirrored by the
extent to which photo-reduction arose with the un-attenuated beam. There is evidence that these same
processes arise in mammalian brain tissue [13,14], and in this context, it is important to confirm the
underlying mechanism(s) responsible for the observed chemical reduction of these metal species.
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combination fitting (LCF) of the spectra in (a) and (b), and cupric and cuprous standards (Cu(II)SO4) 
and [Cu(I)-glutathione] were used for (c) and (d); the results from the LCF are tabulated in each panel; 
below the experimentally-acquired XANES spectra are the reference standards used to fit them for 
each time point (a)–(d). In (a) and (b), inclusion of a small contribution from iron(III) ammonium 
citrate in the LCF resulted in improved quality of fit. χ2 values are as follows for t0 and t1wk fits, 
respectively: (a) 0.06, 0.03; (b) 0.04, 0.02; (c) 0.07, 0.06; (d) 0.002, 0.04. Traces for metal-peptide 
incubations are vertically offset from the reference standards for clarity. 
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Having surveyed larger sample areas (~mm2) with XRF in Section 3.1, using XANES to gain an 
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and (b) α-syn on the oxidation state of Fe, and (c) β and (d) α-syn on the oxidation state of Cu. Ferric
and ferrous standards (Fe(III)Cl3 and [Fe(II) + 1,10-phenanthroline], respectively) were used for linear
co bination fitting (LCF) of the spectra in (a) and (b), and cupric and cuprous standards (Cu(II)SO )
and [Cu(I)-glutathione] were used for (c) and (d); the results from the LCF are tabulated in each panel;
below the experimentally-acquired XANES spectra are the reference standards used to fit them for each
time point (a)–(d). In (a) and (b), inclusion of a small contribution from iron(III) ammonium citrate in
the LCF resulted in improved quality of fit. χ2 values are as follows for t0 and t1 k fits, respectively: (a)
0.06, 0.03; (b) 0.04, 0.02; (c) 0.07, 0.06; (d) 0.002, 0.04. Traces for metal-peptide incubations are vertically
offset from the reference standards for clarity.
3.2. Nanoscale Chemical Speciation of Aβ/Iron Aggregate Structures Formed In-Vitro
Having surveyed larger sample areas (~mm2) with XRF in Section 3.1, using XANES to gain
an overview of dominant inorganic phases at a cellular resolution, soft X-ray spectromicroscopy
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techniques complemented by transmission electron microscopy were used to probe intact protein/metal
structures at length scales spanning tens of nanometers to microns.
3.2.1. Amyloid β(1–42) and Iron(III) In-Vitro
The morphology, spatial distribution of chemical elements, and the composition of aggregate
structures formed through the co-incubation of Aβ(1–42) and iron(III) in vitro were determined using
STXM and TEM (Figure 3). TEM (Figure 3a) revealed aggregate morphology that is largely fibrillar,
approximately 25 µm in diameter and of varying electron density, containing multiple electron opaque
regions (see Appendix B Figure A6 for high magnification TEM images). To establish the chemical
composition of the aggregate at a nanoscale spatial resolution, STXM speciation maps were collected at
the carbon K-edge (to visualize peptide (Aβ) content) and the iron L3-edge. Carbon K-edge mapping
(Figure 3b) showed that peptide distribution closely follows the aggregate morphology under TEM
(Figure 3a), demonstrating the aggregate to be composed of Aβ. Iron L3-edge mapping (Figure 3c)
showed multiple regions of the iron accumulation within the aggregate, suggesting the co-deposition of
Aβ and iron. By comparing the TEM images with the STXM iron speciation map, it is apparent that the
most electron dense regions in Figure 3a correspond to regions of high iron loading within the aggregate
(Figure 3c). It is interesting that in mouse models of amyloid over-production (e.g., APP/PS1), there
is evidence of a direct correspondence between amyloid deposition and iron deposition [14], while
the distribution of iron in human amyloid deposits is far more heterogeneous [13,16]. Our findings
presented here are consistent with the prior work on human amyloid plaque material.
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peptide speciation map. (c) Iron L3-edge speciation map. (d) Composite image displaying peptide 
(cyan) and iron (red) content of the aggregate. (e) Carbon K-edge x-ray absorption spectra from the 
aggregate regions highlighted in (b) and (d). (f) Iron L2,3-edge x-ray absorption spectra (colored 
circles) from the aggregate regions highlighted in (c). The solid lines for the spectra correspond to the 
best fit curve created by superposition of suitably scaled iron reference x-ray absorption spectra. 
3.2.2. STXM Spectromicroscopy of Aβ(1–42) and Iron(III) In Vitro 
To examine the organic composition of the Aβ/iron aggregate in more detail, STXM 
measurements were performed over the entire carbon K-edge (280–320 eV). The resulting x-ray 
absorption spectra obtained from the examined areas (highlighted in Figure 3(b, d)) are displayed in 
Figure 3. TEM and STXM analysis of an Aβ/iron aggregate formed in-vitro. (a) TEM image. Arrowhead
shows a crystalline artefact originating from the buffer medium. (b) Carbon K-edge peptide speciation
map. (c) Iron L3-edge speciation map. (d) Composite image displaying peptide (cyan) and iron (red)
content of the aggregate. (e) Carbon K-edge X-ray absorption spectra from the aggregate regions
highlighted in (b) and (d). (f) Iron L2,3-edge X-ray absorption spectra (colored circles) from the aggregate
regions highlighted in (c). The solid lines for the spectra correspond to the best fit curve created by
superposition of suitably scaled iron reference X-ray absorption spectra.
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3.2.2. STXM Spectromicroscopy of Aβ(1–42) and Iron(III) In Vitro
To examine the organic composition of the Aβ/iron aggregate in more detail, STXM measurements
were performed over the entire carbon K-edge (280–320 eV). The resulting X-ray absorption spectra
obtained from the examined areas (highlighted in Figure 3b,d) are displayed in Figure 3e. Spectrum E1
was obtained from a region of the aggregate containing little to no iron, and comprised two sharp peak
features at 285.2 eV and 288.3 eV, corresponding to the 1s-to-pi* transitions of peptide aromatic and
amide groups respectively [58]. Conversely, spectrum E2 was acquired from a region of the aggregate
containing a high level of iron. By comparing spectrum E2 to E1, a suppression of the 285.2 eV peak
can be seen, along with a broadening of the sharp 288.3 eV feature. These results suggest that the
alterations to Aβ organic composition may occur upon iron loading.
Further STXM measurements were performed over the iron L2,3-edge to determine the chemical
composition of the iron within the aggregate. The relative proportion of iron phases contributing
to each iron L2,3-edge absorption spectrum was calculated using a non-linear least-squares fitting
procedure, as previously described [13]. The reference iron spectra are displayed in Appendix B
Figure A5 Iron L2,3-edge X-ray absorption spectra from three regions of the aggregate (Figure 3c) are
shown in Figure 3f. The fitting of the spectrum obtained from region F1 showed this spectrum to be
primarily (81%) composed of Fe(III) with a minor (19%) contribution from Fe(II). The ferric content
of this region is evidenced by the presence of a low energy peak at 708 eV followed by a dominant
709.5 eV peak at the L3-absorption edge both arising from Fe(III) cations (Appendix B Figure A5) [60].
The fitting of the X-ray absorption spectra from regions F2 and F3 also showed Fe(III) to be the primary
component, but with evidence of increased Fe(II) content (29% and 35% respectively) compared to
region F1. This was made apparent by an enhancement in the intensity of the L3-edge peak feature at
708 eV, the principal Fe(II) absorption peak (Appendix B Figure A5) [60], with respect to the Fe(III)
feature at 709.5 eV.
Taken together, these X-ray spectromicroscopy results demonstrate the sensitivity of STXM to
spatial and chemical composition, allowing the detection of localized changes.
3.3. Mass Spectrometry Allowed Determination of the Specific Binding Regions in [α-syn + Cu], [α-syn + Fe],
[Aβ + Cu], and [Aβ + Fe] Complexes
Having used X-ray methods to image chemical properties on the micro- and nanoscale, the
series of peptide/metal mixtures examined by XANES was analyzed using mass spectrometry (MS) to
determine the regions on the peptides that bind the transition metals Cu and Fe.
A 1:1 complex of Aβ and Fe(II) was generated in an aqueous solution containing 12.5 µM peptide,
200 µM FeCl2, and 20 mM ammonium acetate, with 400 µM hydroxylamine hydrochloride added
to protect Fe(II) from the oxidation by atmospheric air. The resulting 1:1 complex was detected by
MS, as a peak corresponding to a mass increase of 53.939 Da (4565.209 Da compared to 4511.270 Da),
matching the replacement of two protons with Fe, was observed at approximately 10% of the intensity
of the peak corresponding to the apo-peptide. The [Aβ + 2H + Fe]4+ charge state was selected (m/z
1142.305) and interrogated with CID using a potential offset of 30 V. Due to the limited resolution of
the quadrupole mass filter, some co-isolation of [Aβ + 3H + Na]4+ at m/z 1134.320 occurred. As this
adduct seems somewhat more stable than the Fe adduct toward collisional activation, the signal due to
the Na adduct is abundant in the fragmentation spectrum (Figure 4). However, due to the high mass
accuracy and resolving power of FTICR-MS, this does not interfere with the detection and assignment
of Fe-containing fragments.
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of Aβ(1–42) is shown at the bottom, with the possible binding region colored purple.
Following a similar methodology as for Aβ, a 1:1 complex of Fe(II):α-syn was detected by ESI-MS
in a solution containing 7 µM protein, 140 µM FeCl2, and 280 µM hydroxylamine hydrochloride.
This resulted in the observation of the adduct with a signal intensity of approximately 35% of that
associated with the apo-protein. The [α -syn + 11H + Fe]13+ charge state of this complex was then
selected (m/z 1116.787) and interrogated with the collision-induced dissociation using a potential offset
of 16 V.
The presence of an Fe(II)-containing N-terminal b137 fragment in the CID spectrum of [α-syn
+ 11H + Fe(II)]13+ provides evidence that the binding site is located within the first 137 amino acid
residues (Figure 5). Meanwhile, the smallest C-terminal fragment carrying the metal is y21, indicating
a binding site within the last 21 residues. Combined, these results indicate that the binding region is
located in the P(120)DNEAYEMPSEEGYQDYE(137) stretch of the protein.
Similarly, the CID spectrum of [α-syn + 13H + Fe(III)-NTA3-]13+ (Appendix A Figure A3)
shows that the binding region for the 3+ oxidation state of iron was very similar, i.e.,
D(119)PDNEAYEMPSEEGYQ(134). Based on these results, it is likely that coordination in both
cases involves the side-chains of the D, E and/or Y residues present in this region, as suggested by
other methods [18,61].
The presence of an N-terminal c17 fragment bound to copper in the ECD spectrum of [α-syn +
11H + Cu(II)]13+ (Appendix A Figure A4) shows that the highest-affinity binding region for this metal
is located in the 17 residues closest to the N-terminus, i.e., M(1)DVFMKGLSKAKEGVVA(17).
A b14 fragment carrying Fe(II) is observed in the CID spectrum of [Aβ + 2H + Fe(II)]4+ (Figure 4)
indicating that binding occurs in the D(1)AEFRHDSGYEVHH(14) stretch of the peptide. This interaction
is most likely mediated through the histidine residues in this region. In contrast to α-syn, which was
found to bind iron and copper in two distinct sequence regions, both Fe(III) and Cu(II) bind to Aβ in a
very similar region to Fe(II) as the authors have shown recently [59], which is consistent with prior
evidence in the literature [18,61–64].
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4. Discussion
The complexes of Aβ(1–42) or α-syn with copper or iron were studied using XANES, STXM,
and MS. XANES analysis of the four complexes prepared in vitro (Fe(III) or Cu(II) co-incubated with
Aβ(1–42) or α-syn), howed that X-ray-beam-induc photo-reduction was successfully mitigated
with appropriate beam attenuation prior to the fi al s ries of measurements on previously unanalyz
regions of each sample. It was necessary t test for optimal conditi ns prior to each measurement, as
excessive beam attenuation co promised S/N ratios. As noted in the results, XANES experiments
cond cted under thes controlled conditions revealed that the chemical reducti n of ferric iron and
cupric copper arose when each metal was incubated in the presence of Aβ(1–42) for one week, and to
a lesser extent for ferric iron incubated with α-syn. Under these conditions, Aβ(1–42) a peared to
have a greater reductive c pacity than α-syn. The eas with which the photo-reduction of th metals
uld be achieved parall led the extent to which the hemical reduction of the m tals arose during
incubation with the peptides. This raises the possibility that the m chanism(s) responsible for the
chemical reduction of Fe or Cu co-i cubated with Aβ(1–42), and to an extent wit α-syn, are amplified
with X-ray beam exposur .
STXM examination of aggregates formed via the co-incubation of Aβ(1–42) and Fe(III)
in vitro, perfor ed at the carbon K and iron L3-absorption edges, explored multiple regions f
iron co-precipitation in a pepti e-dense ggregate structure of approximately 25 µm in diameter.
The heter ge eity of iron loading was evident, and in the regions of iron loadi g, peptide and
iron distribution were closely correlate , indicating that iron was incorporated into the aggregating
Aβ(1–42) structure. TEM imaging performed subsequent to STXM analysis appeared to confirm this
correlation of Aβ(1–42) and iron distribution, with iron-loaded regions presenting as electron-dense
fibrillar structures within the Aβ aggregate.
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By performing STXM measurements across the entire carbon K-edge, the organic composition of
Aβ was shown to be altered dependent on iron co-localization. In aggregate regions devoid of iron,
Aβ provided carbon K-edge absorption spectra consistent with the theoretical spectrum for Aβ(1–42)
(see Figure 2 in [28]) and albumin peptide references [14]. However, in aggregate regions containing
high levels of iron, an altered spectrum was recorded, displaying a suppressed aromatic absorption
peak, and a broadened amide absorption peak.
An examination of the aggregate iron across the iron L2,3,-absorpotion edge showed a
spatially-dependent variation in the iron oxidation state. Iron L2,3-edge X-ray absorption spectra
from all three regions were found to primarily comprise Fe3+ with more minor contributions from
Fe(II) cations. The Fe(II) content was seen to vary from 19% to 35% across the different regions, again
demonstrating a heterogeneity in sample chemistry within an individual aggregate structure.
These findings demonstrate the power of STXM for the examination of heterogeneous sample
materials on a spatial scale relevant to pathological lesions commonly found in neurodegenerative
disorders (typically <20 µm). Whilst only the carbon and iron content of Aβ/iron structures were
examined in this instance, the large operational energy range typically offered by STXM microscopes
allows for the examination of absorption edges throughout the water window (e.g., C, N, O and P), and
multiple metals (such as Fe, Cu and Ca) implicated in the development of neurodegenerative disorders [65].
This chemical sensitivity of STXM combined with nanoscale spatial resolution, enables the distribution
and chemical speciation of protein/metal structures to be realized to an extremely high level of detail.
Importantly, these qualities allow the identification of localized (sub-micron) changes to both organic and
inorganic sample chemistry that would not be revealed by an analysis on the microscale.
Mass spectrometry of the in-vitro series of Aβ(1–42) or α-syn, incubated with copper or iron,
confirmed that both iron and copper were coordinated by the histidine-rich N-terminal domain of Aβ,
but bound to different regions in α-syn. In α-syn, iron was coordinated by the C-terminal domain,
which is rich in aspartic and glutamic acid residues. Copper(II) preferred the N-terminal domain, and
may be coordinated by the thioether sulfur of the two methionine residues in this region [18,66]; an
alternative lower-affinity site for Cu(II) is near the C-terminus. As highlighted in Figure 2, a small but
consistent improvement in the χ2 value obtained with the linear combination fitting of the XANES
spectra was observed if, in addition to iron(III) chloride, a minor contribution of iron(III) ammonium
citrate (approximately 40% of that of FeCl3) was included as a standard. This can be rationalized in
light of our MS results, as Fe(III) in the citrate complex is coordinated by oxygen ligands, similar to
the coordination by nitrogen (histidine; in Aβ) or oxygen (aspartic/glutamic acid; in α-syn) ligands
in the peptide/protein complexes. These results showcase the power of native top-down MS [53]
to investigate peptide-metal complexes on a molecular scale, as the authors have recently explored
in-depth [59]. Importantly, in these experiments, extremely small sample amounts (picomoles) were
sufficient to obtain high-quality (tandem) MS data.
The precise relationship between the metal coordination and reductive capacity of these species
is still under investigation. As Fe(II) and Cu(I) can easily re-oxidize in aqueous solution, it can be
envisaged that the redox chemistry of these complexes can drive oxidative stress and neuron damage in
the proteinopathies. Improving the understanding of the bioinorganic chemistry of these molecules may
create opportunities to improve the treatment strategies for this class of neurodegenerative disorders.
In conclusion, elucidating the chemistry of these metal-biomolecule complexes is critical for
understanding the etiology of neurodegenerative diseases, and this improved understanding may, in
the longer term, open up new avenues for treatment.
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Figure A3. Tandem MS analysis of the [α-syn + Fe(III)] complex, showing results from CID 
fragmentation of [α-syn + 13H + Fe(III)-NTA3-]13+. The fragments are summarized below the mass 
spectrum, and the possible binding region is indicated. A 3D structural representation of α-syn is 
shown at the bottom, with the possible binding region colored purple. Fe(III) was added as a 1:1 
complex with NTA3- to stabilize it towards hydrolysis, precipitation, and aggregation at pH 7. The 
ligand is lost before backbone fragmentation occurs, and hence metal-bound fragments are detected 
carrying the free Fe(III) cation. 
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below the mass spectrum, and the possible binding region is indicated. A 3D structural representation
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Appendix B: Soft X-Ray Spectromicroscopy. 
 
Figure B1. Reference iron L2,3-edge x-ray absorption spectra for ferric (FeO(OH); blue), ferrous (FeCl2; 
red) and magnetite (Fe3O4; green) iron phases. 
 
Figure B2. Additional high magnification TEM images from the aggregate shown in Figure 3. 
  
Figure A5. Reference iron L2,3-edge X-ray absorption spectra for ferric (FeO(OH); blue), ferrous (FeCl2;
red) and magnetite (Fe3O4; green) iron phases.
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Note that for the highest photon flux condition (a), the successive scans are similar as a consequence 
of significant photo-reduction affecting both scans; (d) XANES from multiple spots on the same 
sample demonstrate homogeneity, with the results of the linear combination fitting matching to 
within 3% between the four sites (spot 1—spot 4) sampled at ~100 μm apart). 
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Appendix D Mass Spectrometry Peak Assignment Tables
Table A1. Collision-induced dissociation of [α-syn + Fe(III)-NTA].
Ion Exact m/z Observed m/z Error (ppm)
[y6]+ 723.2832 723.2835 0.3
[y7]+ 851.3418 851.342 0.3
[b116]11+ 1062.6557 1062.6562 0.4
[b116+Fe(III)]1 + 1067.4659 1067.4663 0.4
[b1 8]11+ 1080.4849 1080.4854 0.4
[b119]11+ 1 90.9419 1090.9433 1.2
[y140+Fe(III)]13+ 1116.7096 1116.71 0.3
[b134+Fe(III)]12+ 1149.4952 1149.4948 −0.4
[b115]10+ 1155.7165 1155.7171 0.5
[b116]10+ 1168.8206 1168.8209 0.3
[b136+Fe(III)]12+ 1172.6694 1172.6705 0.9
[b137+Fe(III)]12+ 1183.4229 1183.4232 0.2
[y22+Fe(III)]2+ 1315.9455 1315.9458 0.2
[y24+Fe(III)]2+ 1414.0061 1414.0067 0.4
[y13]+ 1513.5966 1513.5967 0.1
[y14]+ 1644.6371 1644.6362 −0.5
Average 0.32
Standard Dev 0.41
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Table A2. Collision-induced dissociation of [α-syn + Fe(II)].
Ion Exact m/z Observed m/z Error (ppm)
[y3]+ 316.1504 316.1504 0.3
[y4]+ 445.193 445.1929 −0.2
[y6]+ 723.2832 723.2834 0.3
[y7]+ 851.3418 851.3426 1.0
[y24+Fe(II)]3+ 943.3424 943.343 0.6
[b89]9+ 981.2003 981.2009 0.6
[b118]12+ 990.5285 990.5304 2.0
[b92]9+ 1008.2138 1008.215 1.2
[b112]11+ 1018.2745 1018.2755 1.0
[b113]11+ 1028.5548 1028.5555 0.7
[b114]11+ 1040.286 1040.2868 0.8
[b115]11+ 1050.743 1050.7432 0.2
[b116]11+ 1062.6557 1062.6561 0.3
[y9]+ 1071.4266 1071.4268 0.1
[b127]12+ 1079.2265 1079.2263 −0.2
[b118]11+ 1080.4849 1080.4851 0.1
[b119]11+ 1090.9419 1090.9421 0.1
[y28+Fe(II)]3+ 1106.0738 1106.0726 −1.0
[b111]10+ 1108.6928 1108.6937 0.8
[y140]13+ 1112.6395 1112.6405 0.9
[b140+Fe(II)]13+ 1115.4017 1115.4025 0.7
[y140+Fe(II)]13+ 1116.7872 1116.7873 0.1
[b112]10+ 1120.0012 1120.0012 0.0
[b113]10+ 1131.3096 1131.3099 0.3
[b123]11+ 1132.3206 1132.3218 1.1
[b124]11+ 1138.7785 1138.7784 −0.1
[b114]10+ 1144.2139 1144.2139 0.0
[b125]11+ 1153.6025 1153.6022 −0.2
[b115]10+ 1155.7165 1155.7166 0.0
[b126]11+ 1165.3336 1165.3337 0.1
[b116]10+ 1168.8206 1168.8206 0.0
[b137]12+ 1179.0136 1179.0136 0.0
[b137+Fe(II)]12+ 1183.5069 1183.5072 0.2
[b118]10+ 1188.4327 1188.4326 −0.1
[b119]10+ 1199.9354 1199.9355 0.0
[b131]11+ 1217.4436 1217.4437 0.0
[b132]11+ 1222.6274 1222.6259 −1.2
[b134]11+ 1249.093 1249.0937 0.6
[b124]10+ 1252.5556 1252.5544 −1.0
[y21+Fe(II)]2+ 1258.9359 1258.9364 0.4
[b126]10+ 1281.7662 1281.7663 0.0
[b127]10+ 1294.8703 1294.8713 0.8
[b116]9+ 1298.5776 1298.578 0.3
[y22+Fe(II)]2+ 1316.4494 1316.4494 −0.1
[y24+Fe(II)]2+ 1414.51 1414.5111 0.8
[y25+Fe(II)]2+ 1480.0303 1480.0317 1.0
[y13]+ 1513.5966 1513.5984 1.2
[y26+Fe(II)]2+ 1537.5437 1537.5462 1.6
[y27+Fe(II)]2+ 1602.065 1602.0663 0.8
[y14]+ 1644.6371 1644.6396 1.5
[y15]+ 1773.6796 1773.679 −0.3
Average 0.36
Standard Dev 0.63
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Table A3. Collision-induced dissociation of [Aβ + Fe(II)].
Ion Exact m/z Observed m/z Error (ppm)
[b6]+ 756.3424 756.3424 0.0
[b13]2+ 772.3317 772.3321 0.5
[b14]2+ 840.8612 840.8609 −0.3
[b14+Fe(II)]2+ 867.8208 867.8203 −0.6
[b7]+ 871.3694 871.3693 −0.1
[b15]2+ 904.8904 904.8903 −0.1
[b33]4+ 914.4486 914.4484 −0.3
[b23]3+ 920.0930 920.0917 −1.5
[b33+Fe(II)]4+ 927.9284 927.9271 −1.4
[b24]3+ 953.1158 953.1152 −0.7
[b34+Fe(II)]4+ 956.1994 956.1987 −0.8
[b16]2+ 968.9379 968.9357 −2.3
[b25]3+ 972.1230 972.1219 −1.1
[b35+Fe(II)]4+ 988.9595 988.9590 −0.5
[b36+Fe(II)]4+ 1013.7267 1013.7269 0.3
[b37+Fe(II)]4+ 1027.9820 1027.9809 −1.1
[b38+Fe(II)]4+ 1042.2374 1042.2368 −0.6
[b39+Fe(II)]4+ 1067.0045 1067.0040 −0.5
[b18]2+ 1075.0142 1075.0129 −1.1
[b28]3+ 1081.8463 1081.8454 −0.8
[b40+Fe(II)]4+ 1091.7716 1091.7710 −0.5
[b41+Fe(II)]4+ 1120.0426 1120.0429 0.3
[b30]3+ 1124.5325 1124.5312 −1.2
[Aβ+3H+Na]4+ 1134.3202 1134.3200 −0.2
[b42+Fe(II)]4+ 1137.8019 1137.8008 −1.0
[Aβ+2H+Fe(II)]4+ 1142.3045 1142.3048 0.2
[b19]2+ 1148.5484 1148.5461 −2.0
[b31]3+ 1162.2272 1162.2275 0.3
[b10]+ 1178.4862 1178.4860 −0.2
[b32]3+ 1199.9219 1199.9220 0.1
[y35+Na]3+ 1221.9705 1221.9705 0.0
[b33+Fe(II)]3+ 1236.9021 1236.9009 −1.0
[b34]3+ 1256.6237 1256.6254 1.3
[b34+Fe(II)]3+ 1274.5968 1274.5957 −0.9
[b11]+ 1307.5288 1307.5297 0.7
[b35+Fe(II)]3+ 1318.2770 1318.2779 0.7
[b22]2+ 1322.1224 1322.1225 0.0
[b36]3+ 1333.3267 1333.3287 1.5
[b23]2+ 1379.6359 1379.6386 2.0
[b38+Fe(II)]3+ 1389.3141 1389.3165 1.7
[b12]+ 1406.5972 1406.5977 0.3
[b39+Fe(II)]3+ 1422.3369 1422.3377 0.6
[b24]2+ 1429.1701 1429.1705 0.2
[b40+Fe(II)]3+ 1455.3597 1455.3625 1.9
[b13]+ 1543.6561 1543.6578 1.1
Average −0.16
Standard Dev 0.97
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Table A4. Electron-capture dissociation of [α-syn + Cu(II)].
Ion Exact m/z Observed m/z Error (ppm)
[c6]+ 769.3736 769.3736 0.0
[c9]+ 1026.5111 1026.5095 1.6
[c17+Cu(II)]2+ 935.4487 935.4486 0.1
[c22+Cu(I)]2+ 1186.0824 1186.0817 0.5
[c28+Cu(I)]2+ 1492.2439 1492.2419 1.4
[c31+Cu(I)]2+ 1591.7918 1591.7892 1.6
[c23+Cu(II)]3+ 833.4197 833.4196 0.2
[c28+Cu(II)]3+ 994.8291 994.8276 1.5
[c31+Cu(II)]3+ 1061.1943 1061.1922 2.0
[c33+Cu(I)]3+ 1137.9112 1137.9096 1.4
[c35+Cu(I)]3+ 1223.6237 1223.6213 1.9
[c38+Cu(I)]3+ 1313.3483 1313.3462 1.6
[c39+Cu(I)]3+ 1367.7028 1367.7026 0.1
[c46+Cu(I)]3+ 1610.8368 1610.8379 −0.7
[c38+Cu(I)]4+ 985.2631 985.2613 1.8
[c39+Cu(I)]4+ 1026.0289 1026.0269 1.9
[c50+Cu(II)]5+ 1045.1469 1045.1460 0.9
[c57+Cu(II)]5+ 1170.6114 1170.6118 −0.3
[c61+Cu(I)]5+ 1268.0690 1268.0696 −0.4
[c68+Cu(II)]7+ 999.5258 999.5248 1.1
[c75+Cu(II)]7+ 1089.1486 1089.1479 0.6
[c75]7+ 1080.4466 1080.4454 1.1
[c95+Cu(II)]9+ 1050.5581 1050.5583 −0.2
[c96+Cu(II)]9+ 1064.7909 1064.7905 0.4
[c139+Cu(I)]11+ 1313.8364 1313.8377 −1.0
[z4+H]+ 429.1748 429.1749 −0.3
[z46+H]3+ 1723.0915 1723.0913 0.1
[z45+H]3+ 1690.0687 1690.0696 −0.5
[z57+H]4+ 1518.4317 1518.4329 −0.8
[z65+H]5+ 1380.2378 1380.2380 −0.2
[z102+H]8+ 1323.1481 1323.1489 −0.6
[z101+H]8+ 1302.7652 1302.7661 −0.8
[z113]9+ 1296.5308 1296.5318 −0.8
[z112+H]9+ 1282.3046 1282.3062 −1.2
[z102+H]9+ 1176.2435 1176.2431 0.4
[z140+Cu(I)]10+ 1450.6188 1450.6190 −0.1
[z140+Cu(I)]11+ 1318.8360 1318.8374 −1.1
[z140+Cu(I)]12+ 1209.0169 1209.0177 −0.7
Average 0.33
Standard Dev 0.98
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